Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 9/20 | 0.53 |
| ▸ | RARG | P13631 | 8/20 | 0.53 |
| ▸ | RARA | P10276 | 7/20 | 0.53 |
| ▸ | RXRA | P19793 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6430338 | 1.00 | RARB (0.53) | RARBRARGRARARXRAALDH1A1 | |
| SCHEMBL7930761 | 0.91 | RARB (0.51) | RARBRARGRARARXRAALDH1A1 | |
| SCHEMBL1683960 | 0.88 | RARB (0.48) | RARBRARGRARARXRAALDH1A1 | |
| SCHEMBL1683959 | 0.88 | RARB (0.48) | RARBRARGRARARXRAALDH1A1 | |
| SCHEMBL1683993 | 0.84 | RARB (0.53) | RARBRARGRARARXRAALDH1A1 | |
| SCHEMBL1683992 | 0.84 | RARB (0.53) | RARBRARGRARARXRAALDH1A1 | |
| SCHEMBL1683989 | 0.83 | RARB (0.45) | RARBRARGRARARXRAALDH1A1 | |
| SCHEMBL2941525 | 0.83 | RARB (0.45) | RARBRARGRARARXRAALDH1A1 | |
| SCHEMBL8175917 | 0.80 | TDP1 (0.43) | RARBRARGRARAALDH1A1SMN1; SMN2 | |
| SCHEMBL2909230 | 0.80 | RARB (0.53) | RARBRARGRARARXRAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| US-6858647-B2 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-02-22 | — | — | US | claimed |
| US-20030055110-A1 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-03-20 | — | — | US | claimed |
| EP-0879814-B1 | Triaromatic compounds, compositions containing them and uses thereof | CT INTERNAT DE BR RECH S DERMA (FR) | 2001-11-28 | — | — | EP | claimed |
| US-6150413-A | TREATMENT OF DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, BONE AND OPHTHALMOLOGICAL DISORDERS, AS WELL AS MAMMALIAN SKIN AND HAIR CONDITIONS; 4-(4-(BIPHENYL-2-YL)BUT-3-EN-1-YNYL)BENZOIC ACID, FOR EXAMPLE | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 2000-11-21 | — | — | US | claimed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | disclosed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | disclosed |
| US-6858647-B2 | Retinoid compounds suited for antibacterial applications | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-02-22 | — | — | US | disclosed |
| EP-0879814-B1 | Triaromatic compounds, compositions containing them and uses thereof | CT INTERNAT DE BR RECH S DERMA (FR) | 2001-11-28 | — | — | EP | disclosed |
| US-6150413-A | TREATMENT OF DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, BONE AND OPHTHALMOLOGICAL DISORDERS, AS WELL AS MAMMALIAN SKIN AND HAIR CONDITIONS; 4-(4-(BIPHENYL-2-YL)BUT-3-EN-1-YNYL)BENZOIC ACID, FOR EXAMPLE | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 2000-11-21 | — | — | US | disclosed |
| EP-0879814-A1 | Triaromatic compounds, compositions containing them and uses thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1998-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | RARB 987/4885RARG 744/4885RARA 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.